Obstructive Sleep Apnea and Hypertension-mediated Organ Damage in Nonresistant and Resistant Hypertension
Overview
Authors
Affiliations
The potential role of obstructive sleep apnea (OSA) in hypertension-mediated organ damage (HMOD) may be influenced by the presence of resistant hypertension (RH). Herein, we enrolled patients with hypertension from a tertiary center for clinical evaluation and performed a sleep study to identify OSA (apnea-hypopnea index ≥15 events/h) and a blinded analysis of four standard HMOD parameters (left ventricular hypertrophy [LVH], increased arterial stiffness [≥10 m/s], presence of retinopathy, and nephropathy). RH was diagnosed based on uncontrolled blood pressure (BP) (≥140/90 mmHg) despite concurrent use of at least three antihypertensive drug classes or controlled BP with concurrent use of ≥4 antihypertensive drug classes at optimal doses. To avoid the white-coat effect, ambulatory BP monitoring was performed to confirm RH diagnosis. One-hundred patients were included in the analysis (mean age: 54 ± 8 years, 65% females, body mass index: 30.4 ± 4.5 kg/m²). OSA was detected in 52% of patients. Among patients with non-RH (n = 53), the presence of OSA (52.8%) was not associated with an increased frequency of HMOD. Conversely, among patients with RH, OSA (51.1%) was associated with a higher incidence of LVH (RH-OSA,61%; RH + OSA,87%; p = 0.049). Logistic regression analysis using the total sample revealed that RH (OR:7.89; 95% CI:2.18-28.52; p = 0.002), systolic BP (OR:1.04; 95% CI:1.00-1.07; p = 0.042) and OSA (OR:4.31; 95% CI:1.14-16.34; p = 0.032) were independently associated with LVH. No significant association was observed between OSA and arterial stiffness, retinopathy, or nephropathy. In conclusion, OSA is independently associated with LVH in RH, suggesting a potential role of OSA in RH prognosis.
Shiina K Hypertens Res. 2024; 47(11):3085-3098.
PMID: 39210083 PMC: 11534699. DOI: 10.1038/s41440-024-01852-y.
Sleep and hypertension - up to date 2024.
Tomitani N, Hoshide S, Kario K Hypertens Res. 2024; 47(12):3356-3362.
PMID: 39152257 DOI: 10.1038/s41440-024-01845-x.
Cheng H, Li C, Lin C J Clin Hypertens (Greenwich). 2024; 26(9):1090-1097.
PMID: 39037154 PMC: 11488309. DOI: 10.1111/jch.14871.
The Global Burden of Resistant Hypertension and Potential Treatment Options.
Buso G, Agabiti-Rosei C, Lemoli M, Corvini F, Muiesan M Eur Cardiol. 2024; 19:e07.
PMID: 38983582 PMC: 11231817. DOI: 10.15420/ecr.2023.51.
Yao X, Li N, Heizhati M, Wang Y, Ma Y, Wang R Cardiovasc Diagn Ther. 2024; 13(6):968-978.
PMID: 38162112 PMC: 10753244. DOI: 10.21037/cdt-23-284.